Newsletter Subject

Kills more cancer cells than a dose of radiation

From

americanshealth.com

Email Address

americanshealth@americanshealth.com

Sent On

Thu, Sep 19, 2024 11:02 AM

Email Preheader Text

September 19, 2024 Dear Reader, In 1918, this "" was in every household in America. Valuable enough

September 19, 2024 Dear Reader, In 1918, this "[miracle medicine](" was in every household in America. Valuable enough to get caught in the crossfire during both World Wars... [green seed]( And powerful enough to be studied by the founding members of a massive Big Pharma dynasty... There was nothing else like it on Earth. In fact, [this miracle medicine]( was on track to become a game-changer for fighting the cancer epidemic. But then it just...disappeared. To this day, it's not being taught in medical schools--or prescribed in major U.S. cancer centers. But the results of lab studies are impressive. Big Pharma knows more about this than they're letting on...and [these newly discovered documents]( prove it... Everything you need to know is [right here](. To your health, Karen Reddel Logical Health Alternatives P.S. No one's talking about this--but this discovery is already changing the lives of cancer patients. [See it here]( before corporate interests make it "disappear" again. This ad is sent on behalf of OmniVistaHealth, LLC. P.O. Box 913, Frederick, MD 21705, USA. If you would like to unsubscribe from receiving offers from OmniVistaHealth, please [click here](. Advertisement Health News Roundup [Superbug crisis could get worse, killing nearly 40 million people by 2050, study estimates](: By 2050, antibiotic-resistant superbugs could cause up to 10 million deaths annually if current trends continue, according to a new report. The study highlights the urgent need for global action to combat antibiotic resistance and improve infection control practices. [FDA expands approval of breast cancer drug Kisqali to earlier stage patients](: The FDA has expanded the approval of the breast cancer drug Kisqali to include use in earlier stages of the disease, offering a new treatment option for patients with HR-positive, HER2-negative breast cancer. This expanded approval is based on promising results from clinical trials demonstrating Kisqali's effectiveness in reducing recurrence rates. Use of this email, website, and content is subject to the Privacy Policy and Terms of Use published on website. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that the sender of this email has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this message and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This email contains Advertisements. Update your email preferences or unsubscribe [here]( © 2024 Americans Health 19354 Watermark Drive, Suite 202 Cornelius, NC 28031, United States of America [[beehiiv logo]Powered by beehiiv]( [Terms of Service](

Marketing emails from americanshealth.com

View More
Sent On

07/12/2024

Sent On

09/11/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

05/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.